Skip to main content
Matthew Laughon, MD, Neonat/Perinatology, Chapel Hill, NC

MatthewMLaughonMD

Neonat/Perinatology Chapel Hill, NC

Professor, Pediatrics, The University of North Carolina at Chapel Hill

Dr. Laughon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Laughon's full profile

Already have an account?

  • Office

    101 Manning Dr
    Chapel Hill, NC 27514
    Phone+1 984-974-1000
    Fax+1 919-966-7772

Education & Training

  • University of North Carolina Hospitals
    University of North Carolina HospitalsFellowship, Neonatal-Perinatal Medicine, 2001 - 2004
  • University of North Carolina at Chapel Hill
    University of North Carolina at Chapel HillMPH, Epidemiology, 2004
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Pediatrics, 1998 - 2001
  • University of Virginia School of Medicine
    University of Virginia School of MedicineClass of 1998
  • Davidson College
    Davidson CollegeB.S., Magna Cum Laude, 1994

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1999 - 2025
  • American Board of Pediatrics Neonatal-Perinatal Medicine

Awards, Honors, & Recognition

  • K30 Scholar-Clinical Research Curriculum NIH, 2003
  • Phi Beta Kappa 1993
  • Samuel H. Bell Honor Scholar Davidson College, 1990

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Agreement of an Echocardiogram-Based Diagnosis of Pulmonary Hypertension in Infants at Risk for Bronchopulmonary Dysplasia Among Masked Reviewers  
    Rachel D Torok, Matthew M Laughon, Andrew W McCrary, Christoph P Hornik, Jennifer S Li, Nature
  • Characterization of the Population Pharmacokinetics of Ampicillin in Neonates Using an Opportunistic Study Design  
    Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Ian-U Chong S, Melloni C, Gao J, Benjamin DK Jr, Capparelli EV, Cohen-Wolkowiez M; on be..., Antimicrob Agents Chemother, 6/1/2014
  • Trends in Caffeine Use and Association between Clinical Outcomes and Timing of Therapy in Very Low Birth Weight Infants  
    Dobson NR, Patel RM, Smith PB, Kuehn DR, Clark J, Vyas-Read S, Herring A, Laughon MM, Carlton D, Hunt CE, J Pediatr, 5/1/2014
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • Sedatives and Analgesics Given To Dying Infants in Neonatal Intensive Care Units.
    Zimmerman KO, Hornik CP, Watt KM, Clark RH, Laughon MM, Smith PB, PAS, 1/1/2014
  • Analysis of the BPCA Priority List: Are Drug Priorities Reflective of Clinical Need in Hospitalized Infants?
    Gostelow M, Tripathi N, Benjamin Jr DB, Hornik CP, Cohen-Wolkowiez M, Clark R, Laughon MM, Smith PB, PAS, 1/1/2014
  • Batton B, Li L, Newman N, Das A, Watterberg K, Yoder B, Faix R, Laughon M, Stoll B, Higgins R, PAS, 1/1/2014
  • Join now to see all

Other

  • Dissemination of Information from Pediatric Studies Conducted under BPCA and PREA. 
    Smith PB, Laughon MM, National Academies of Science Institute of Medicine, Appendix B
    1/1/2013

Press Mentions

  • Prolonged Duration of Early Antibiotic Therapy in Extremely Premature Infants
    Prolonged Duration of Early Antibiotic Therapy in Extremely Premature InfantsJune 1st, 2019
  • Neurodevelopmental Outcomes Among Extremely Premature Infants with Linear Growth Restriction
    Neurodevelopmental Outcomes Among Extremely Premature Infants with Linear Growth RestrictionOctober 23rd, 2018
  • Why Are NICU Drugs Largely Untested?
    Why Are NICU Drugs Largely Untested?September 13th, 2017
  • Join now to see all